PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. PhaseBio is leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s product PB1046 is based on the ELP platform and is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension. PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
PB2452 and PB1046
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):